Letter
. 2019 Jun;37(22).
doi: 10.1200/JCO.19.00504.

Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM

Matthew P Goetz 1 Vera J Suman 1 Yusuke Nakamura 1 Kazuma Kiyotani 1 V Craig Jordan 1 James N Ingle 1 
Affiliations
  • PMID: 31211604
  •     10 References
  •     3 citations

No abstract available

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Vered Stearns, Michael D Johnson, +6 authors, David A Flockhart.
J Natl Cancer Inst, 2003 Dec 05; 95(23). PMID: 14652237
Highly Cited.
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
Matthew P Goetz, James M Rae, +10 authors, James N Ingle.
J Clin Oncol, 2005 Dec 20; 23(36). PMID: 16361630
Highly Cited.
Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
International Breast Cancer Study Group, Marco Colleoni, +6 authors, Richard D Gelber.
J Clin Oncol, 2006 Mar 01; 24(9). PMID: 16505417
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response.
Kazuma Kiyotani, Taisei Mushiroda, +12 authors, Hitoshi Zembutsu.
Pharmacogenet Genomics, 2010 Jun 25; 20(9). PMID: 20574415
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.
Matthew P Goetz, Vera J Suman, +14 authors, James N Ingle.
Clin Cancer Res, 2012 Dec 06; 19(2). PMID: 23213055    Free PMC article.
Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.
Kazuma Kiyotani, Taisei Mushiroda, Hitoshi Zembutsu, Yusuke Nakamura.
J Hum Genet, 2013 May 10; 58(6). PMID: 23657426
Review.
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
M A Province, M P Goetz, +52 authors, International Tamoxifen Pharmacogenomics Consortium.
Clin Pharmacol Ther, 2013 Sep 26; 95(2). PMID: 24060820    Free PMC article.
Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.
P Saladores, T Mürdter, +18 authors, H Brauch.
Pharmacogenomics J, 2014 Aug 06; 15(1). PMID: 25091503    Free PMC article.
Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
Anabel Sanchez-Spitman, Vincent Dezentjé, +12 authors, Henk-Jan Guchelaar.
J Clin Oncol, 2019 Jan 25; 37(8). PMID: 30676859
Highly Cited.
The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
Jeanine Marie Nardin, Werner Schroth, +11 authors, José Claudio Casali-da-Rocha.
Clin Transl Sci, 2019 Oct 02; 13(2). PMID: 31573754    Free PMC article.
Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen.
Lena Klopp-Schulze, Anna Mueller-Schoell, +4 authors, Charlotte Kloft.
Front Pharmacol, 2020 Apr 17; 11. PMID: 32296331    Free PMC article.
Exposure-response analysis of endoxifen serum concentrations in early-breast cancer.
Anabel Beatriz Sanchez-Spitman, Dirk-Jan A R Moes, +5 authors, Henk-Jan Guchelaar.
Cancer Chemother Pharmacol, 2020 May 30; 85(6). PMID: 32468081    Free PMC article.